Table 6.
Biomaterial scaffolds in clinical trials for SCI (https://www.clinicaltrials.gov/, accessed on 1 August 2022).
| Effect on Pathophysiological Events | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Author, Year | Location of Injury | Ongoing Clinical Trials (Identifier) | Phase | Combinatory Agent | Biomaterial Scaffold | Motor Function | Sensory Function | Anti-Inflammation | Scar/Cavity | Axon Growth | Angiogenesis | Facilitation of Cell Migration |
| - | Cervical/Thoracic | NCT02688049 | Phase 1 Phase 2 |
NSCs and MSCs | NeuroRegen scaffold | - | - | - | - | - | - | - |
| - | Cervical/Thoracic | NCT02352077 | Phase 1 | Bone marrow mononuclear cells and MSCs |
NeuroRegen scaffold | - | - | - | - | - | - | - |
| - | Cervical/Thoracic | NCT02688062 | Phase 1 Phase 2 |
Bone marrow mononuclear cells | NeuroRegen scaffold | - | - | - | - | - | - | - |
| - | Thoracic | NCT02138110 | Not Applicable | Poly(lactic-co-glycolic acid)-b-poly(L-lysine) scaffold | - | - | - | - | - | - | - | |
| - | Thoracic | NCT03762655 | Not Applicable | Poly(lactic-co-glycolic acid)-b-poly(L-lysine) scaffold | - | - | - | - | - | - | - | |
| - | Thoracic | NCT02510365 | Phase 1 | Collagen scaffold | - | - | - | - | - | - | - | |
| - | Cervical/Thoracic | NCT03966794 | Phase 1 Phase 2 |
Epidural Electrical Stimulation | Collagen scaffold | - | - | - | - | - | - | - |
| - | Thoracic/Lumbar | NCT02326662 | Phase 1 Phase 2 |
Autologous NSCs | RMx Biomatrix | - | - | - | - | - | - | - |
| Amr SM, et al., 2014 [226] |
Thoracic | - | - | BMSCs/peripheral nerve grafts | Chitosan-laminin scaffold | Several cases improved | Several cases improved | NA | NA | NA | NA | NA |
| Xiao Z, et al., 2018 [237] |
Cervical/Thoracic | - | - | MSCs | NeuroRegen scaffold | Several cases improved | Several cases improved | NA | NA | NA | NA | NA |
| Chen W, et al., 2020 [133] |
Thoracic | - | - | Bone marrow mononuclear cells | NeuroRegen scaffold | - | Several cases improved | NA | NA | NA | NA | NA |
Note: -, no difference with the control group; NA, not available.